Yale New Haven Health
New Haven, Connecticut, 06510, United States
NCT Number: NCT04710563
A research project capturing experiences of patients with critical limb threatening ischemia, with the ultimate goal of setting new standards for diagnosing, describing detailed patient-centered outcomes, and evaluating the variability in therapeutic approaches and their association with outcomes.
This study is active but is not currently recruiting participants.
18 year and older
All sexes
Observational
New Haven, Connecticut, 06510, United States
An estimated 8 million individuals in America are affected by peripheral arterial disease (PAD). One of its extreme expressions is Critical Limb Ischemia (CLI). It is one of the most severe vascular conditions associated with devastating outcomes, including poorly healing wounds, extreme pain, and a high amputation risk. It is also one of the deadliest conditions, with 6-month and 5-year mortality rates estimated to be 20 and >50%, respectively. To date, however, there is a paucity of prospective clinical evidence about the variability in patients' presentations, their management or their outcomes. Accordingly, little progress has been made in adequately staging the disease and to risk-stratify treatment approaches to patients' individual characteristics. What is desperately needed to advance the care and management of patients with CLI is a focused research effort to set new standards for diagnosing, describing detailed patient-centered outcomes, and evaluating the variability in therapeutic approaches and their association with outcomes. The specific aims of SCOPE-CLI are to generate new evidence on the clinical characteristics, treatment patterns and outcomes of patients with critical limb ischemia (CLI); to describe treatment patterns and variability across practices to identify gaps in delivering quality care; and to perform a series of analyses to examine the associations of patient and treatment characteristics with outcomes. The central objective of SCOPE-CLI is to systematically quantify patients' CLI-specific health status and clinical outcomes and to perform subgroup analyses as a function of different PAD treatments and patient characteristics.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Time frame: After enrollment and follow-up at month 1
PAD-specific, multi-dimensional health status instrument with a CLI specific module. Higher scores indicate better functioning.
Time frame: After enrollment and follow-up at month 2
PAD-specific, multi-dimensional health status instrument with a CLI specific module. Higher scores indicate better functioning.
Time frame: After enrollment and follow-up at month 6
PAD-specific, multi-dimensional health status instrument with a CLI specific module. Higher scores indicate better functioning.
Time frame: After enrollment and follow-up at month 12
PAD-specific, multi-dimensional health status instrument with a CLI specific module. Higher scores indicate better functioning.
Time frame: 6 months after enrollment
Major adverse limb events include: major amputation above the level of the ankle joint, thrombolysis/thrombectomy or surgical bypass or graft revision, after diagnostic or interventional lower extremity angiography)
Time frame: 12 months after enrollment
Major adverse limb events include: major amputation above the level of the ankle joint, thrombolysis/thrombectomy or surgical bypass or graft revision, after diagnostic or interventional lower extremity angiography)
Time frame: 5 years after enrollment
Major adverse limb events include: major amputation above the level of the ankle joint, thrombolysis/thrombectomy or surgical bypass or graft revision, after diagnostic or interventional lower extremity angiography)
Time frame: 6 months after enrollment
AFS will be a measure of number of patients "free from death or above ankle amputation"
Time frame: 12 months after enrollment
AFS will be a measure of number of patients "free from death or above ankle amputation"
Time frame: 5 years after enrollment
AFS will be a measure of number of patients "free from death or above ankle amputation"
Time frame: 6 months after enrollment
Vital status obtained from either medical records or social security death index will be assessed to account for number of patients who died
Time frame: 12 months after enrollment
Vital status obtained from either medical records or social security death index will be assessed to account for number of patients who died
Time frame: 5 years after enrollment
Vital status obtained from either medical records or social security death index will be assessed to account for number of patients who died
Yale University
Other
SCOPE-CLI: Shifting Care and Outcomes for Patients With Endangered Limbs - Critical Limb Ischemia
Acronym: SCOPE-CLI
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT04110327
Arterial Occlusive Diseases, Arteriosclerosis
Graz, Austria
View Trial DetailsNCT06832631
Arterial Occlusive Diseases, Arteriosclerosis
Aalst, Belgium
View Trial DetailsNCT04349657
Arterial Occlusive Diseases, Arteriosclerosis
Aalst, Belgium
View Trial DetailsNCT03884257
Arterial Occlusive Diseases, Arteriosclerosis
Graz, Austria
View Trial Details